# OnCo record cardiotoxicity-surveillance-recovery (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/cardiotoxicity-surveillance-recovery/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "cardiotoxicity-surveillance-recovery" ;
  schema:name "Heart function after anthracyclines, trastuzumab and chest radiotherapy"@en ;
  schema:description "Most heart damage from anthracycline chemotherapy appears within the first year after it finishes, and most of it improves at least partly when it is caught and treated. Heart muscle weakened by trastuzumab usually recovers when the drug is stopped. Radiotherapy to the chest raises the risk of coronary disease years later, in proportion to the dose the heart received."@en ;
  schema:url <https://onco.cc/technologies/cardiotoxicity-surveillance-recovery/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cardio-oncology> ;
  schema:citation <https://doi.org/10.1161/CIRCULATIONAHA.114.013777>, <https://doi.org/10.1200/JCO.2009.26.0463>, <https://doi.org/10.1056/NEJMoa1209825>, <https://doi.org/10.1200/JCO.2016.70.5400>, <https://doi.org/10.1093/eurheartj/ehac244> ;
  onco:status "standard-of-care" ;
  onco:tag "rejuvenation", "survivorship", "evidence:strong" ;
  onco:related <https://onco.cc/ideas/idea-moon-cardioprotection-by-default/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/sarcoma/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/cardiac-biomarker-monitoring/>, <https://onco.cc/technologies/strain-echocardiography-gls/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/anthracycline-cardioprotection/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/epirubicin/> ;
  onco:terms <https://onco.cc/terms/trastuzumab-cardiotoxicity/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .